IMRX news

Latest 2 stories · newest Oct 29, 2026

IMRX

Immuneering extends Phase 2 pancreatic trial and accelerates Phase 3 enrollment

Immuneering reported Q3 2026 results, extending the Phase 2 PDAC trial follow-up and expanding the Phase 3 MAPKeeper 301 enrollment target to 570 patients, which may accelerate data to mid-2028. The company also projected a cash runway into Q4 2028.

Guidance Oct 29, 2026 sentiment +0.40 SEC filing ↗

IMRX

Immuneering Reports Q2 2026 Financial Results and Key Updates

Immuneering Corp (IMRX) reported its Q2 2026 financials. The company announced positive interim Phase 2a pancreatic cancer data and is dosing patients in its pivotal Phase 3 MAPKeeper 301 trial.

Earnings Aug 5, 2026 sentiment +0.50 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same IMRX feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/IMRX/newsSTART FREE